160 related articles for article (PubMed ID: 25279503)
1. Bioenergetic differences between MCF-7 and T47D breast cancer cells and their regulation by oestradiol and tamoxifen.
Radde BN; Ivanova MM; Mai HX; Salabei JK; Hill BG; Klinge CM
Biochem J; 2015 Jan; 465(1):49-61. PubMed ID: 25279503
[TBL] [Abstract][Full Text] [Related]
2. Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells.
Radde BN; Ivanova MM; Mai HX; Alizadeh-Rad N; Piell K; Van Hoose P; Cole MP; Muluhngwi P; Kalbfleisch TS; Rouchka EC; Hill BG; Klinge CM
Exp Cell Res; 2016 Sep; 347(1):222-231. PubMed ID: 27515002
[TBL] [Abstract][Full Text] [Related]
3. Estradiol and tamoxifen regulate NRF-1 and mitochondrial function in mouse mammary gland and uterus.
Ivanova MM; Radde BN; Son J; Mehta FF; Chung SH; Klinge CM
J Mol Endocrinol; 2013 Oct; 51(2):233-46. PubMed ID: 23892277
[TBL] [Abstract][Full Text] [Related]
4. Anacardic Acid, Salicylic Acid, and Oleic Acid Differentially Alter Cellular Bioenergetic Function in Breast Cancer Cells.
Radde BN; Alizadeh-Rad N; Price SM; Schultz DJ; Klinge CM
J Cell Biochem; 2016 Nov; 117(11):2521-32. PubMed ID: 26990649
[TBL] [Abstract][Full Text] [Related]
5. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
[TBL] [Abstract][Full Text] [Related]
6. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
[TBL] [Abstract][Full Text] [Related]
7. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
8. Genistein modulates proliferation and mitochondrial functionality in breast cancer cells depending on ERalpha/ERbeta ratio.
Pons DG; Nadal-Serrano M; Blanquer-Rossello MM; Sastre-Serra J; Oliver J; Roca P
J Cell Biochem; 2014 May; 115(5):949-58. PubMed ID: 24375531
[TBL] [Abstract][Full Text] [Related]
9. Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.
Fan P; Cunliffe HE; Griffith OL; Agboke FA; Ramos P; Gray JW; Jordan VC
Eur J Cancer; 2014 Nov; 50(16):2877-86. PubMed ID: 25212499
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites.
Ivanova MM; Luken KH; Zimmer AS; Lenzo FL; Smith RJ; Arteel MW; Kollenberg TJ; Mattingly KA; Klinge CM
FASEB J; 2011 Apr; 25(4):1402-16. PubMed ID: 21233487
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
13. Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade.
Rabenoelina F; Semlali A; Duchesne MJ; Freiss G; Pons M; Badia E
Int J Cancer; 2002 Apr; 98(5):698-706. PubMed ID: 11920638
[TBL] [Abstract][Full Text] [Related]
14. Quercetin reverses tamoxifen resistance in breast cancer cells.
Wang H; Tao L; Qi K; Zhang H; Feng D; Wei W; Kong H; Chen T; Lin Q
J BUON; 2015; 20(3):707-13. PubMed ID: 26214621
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
Murphy CS; Pink JJ; Jordan VC
Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
[TBL] [Abstract][Full Text] [Related]
16. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
17. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
18. Stimulatory effect of oestradiol-17 beta and tamoxifen on gross cystic disease fluid protein 15,000 production and mRNA levels in T47D human breast cancer cells.
Dejardin L; Gol-Winkler R; Collette J; Delvenne C; Carlisi I; Haagensen DE; Franchimont P
J Mol Endocrinol; 1991 Oct; 7(2):105-12. PubMed ID: 1930624
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells.
Park WC; Liu H; Macgregor Schafer J; Jordan VC
Int J Oncol; 2005 Nov; 27(5):1459-66. PubMed ID: 16211243
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells.
Wakeling AE
J Steroid Biochem; 1989; 34(1-6):183-8. PubMed ID: 2696844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
